GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » Float Percentage Of Total Shares Outstanding

Nicox (XPAR:ALCOX) Float Percentage Of Total Shares Outstanding : 0.00% (As of Apr. 17, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Nicox Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nicox's float shares is 0.00 Mil. Nicox's total shares outstanding is 69.01 Mil. Nicox's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nicox's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nicox's Institutional Ownership is 3.16%.

Nicox Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Nicox's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/69.01
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nicox Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
XPAR:ALVAL XPAR:AELIS XPAR:ALDVI XPAR:ALNFL XPAR:POXEL XPAR:ALPAT XPAR:ALVIO XPAR:ALVET XPAR:ALTAO XPAR:ALGEN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NICXF:USA 0RCQ:UK NXOA:Germany
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Website
https://www.nicox.com
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines